FRANCE – Biocorp has entered into an agreement for the development and global distribution of a specific version of its Mallya smart sensor as an accessory for one of Merck KGaA’s drug delivery devices.
The companies are extending their collaboration after an already ongoing program in human growth hormone (HGH).
The device will help patients (children and teenagers) automatically keep track of their HGH daily injection and monitor adherence to their treatment plan.
Mallya is a Bluetooth-enabled clip-on device for pen injectors that collects dose and time of each injection and transfers information in real-time to companion software.
Mallya commercial versions of insulin pen injectors are available in Europe and other regions.
Biocorp and Merck KGaA have agreed to collaborate on the development of a new version of Mallya to assist patients in monitoring self-injections during treatment.
The device will automatically track doses injected with a timestamp and indicate that the product is correctly administered.
Within the first three years of the collaboration, Biocorp will receive up to €5 million (US$4.9 million) for product development.
Additional revenues are expected to reach up to €8 million (US$7.8 million) in the first five years following launch, depending on commercial milestones and patient adoption of Mallya devices by Merck KGaA, with further upside potential in subsequent years.
Biocorp has entered into similar agreements with Sanofi and Novo Nordisk to develop insulin and HGH-specific versions of the Mallya technology.
Global insulin delivery pens market and breakthroughs
The global insulin delivery pens market is expected to be worth US$22.4 billion by the end of 2022, and to grow at an 8.0% CAGR to be worth US$48.6 billion by the end of 2032, as per Future Markets Insights.
The development of insulin pens has increased the effectiveness of diabetes management. Disposable insulin pens contain a prefilled cartridge and are disposed of or thrown away after providing convenient insulin delivery.
Several factors contribute to the global insulin delivery pens market’s expansion. But the major drivers include higher prevalence of diabetes and rising consumer awareness.
Blood glucose monitoring systems market is expected to grow in the coming years owing to the increasing prevalence of diabetes worldwide. Over 537 million adults worldwide suffer from diabetes.
For adequate management of diabetes, proper blood glucose monitoring is necessary, which is expected to increase the demand for blood glucose monitoring systems in the coming years.
Furthermore, the rising prevalence of obesity, which accounts for 80 to 85% of the risk of developing type 2 diabetes, will have an impact on the demand for blood glucose monitoring systems in the coming years.
Furthermore, the transition to technologically advanced glucose monitoring systems, as well as rigorous glucose monitoring product approvals and launches, will contribute to regional market growth.
The blood glucose monitoring systems market has evolved significantly over the years as a result of the active participation of global MedTech companies and technological advancements in the domain.
Smart Meter, the leader in cellular-connected remote patient monitoring (RPM) devices, data, and services, announced the availability of its iGlucose monitor for gestational diabetes management on August 2021.
Terumo launched the Dexcom G6 Continuous Glucose Monitoring (CGM) System, manufactured by Dexcom, Inc., in Japan on July 2021.
DexCom, Inc. and Insulet Corporation announced a commercialization agreement on February 2020, to combine current and future Dexcom continuous glucose monitoring systems (CGM) with Insulet’s trusted tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery, which is currently in pivotal trial.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
